Previous close | 7.48 |
Open | 7.63 |
Bid | 5.45 x 200 |
Ask | 9.58 x 200 |
Day's range | 7.40 - 7.67 |
52-week range | 7.11 - 15.49 |
Volume | |
Avg. volume | 33,952 |
Market cap | 181.018M |
Beta (5Y monthly) | 0.79 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.35 |
Earnings date | 09 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 12.61 |
— So far this year alone, 25 TULSA-related scientific research presentations have been delivered at major medical meetings around the world — — Of those, eight (8) presentations were from leading urologists at AUA 2024 — — Clinical evidence continues to highlight TULSA’s ability to treat an unrivalled variety of patients with localized prostate cancer and/or BPH — TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-s
Key Insights Given the large stake in the stock by institutions, Profound Medical's stock price might be vulnerable to...
TORONTO, April 22, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2024 financial results after market close on Thursday, May 9, 2024. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the